US biotech Magenta Therapeutics (Nasdaq: MGTA) has announced the outcome of a review of its business, including the status of its programs, resources, and capabilities.
Following the review, Magenta is to halt further development of its programs and conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
Options that Magenta is open to include an acquisition, merger, business combination, or other transaction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze